OncoTherapy Science (4564) · RiskRestated
Risk that applications for public subsidies and grants will not be approved
First written in FY2017. 1 of 2 entries say "Restated". Latest entry: FY2018.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of R&D delays due to dependence on national projects and subsidiesA theme 4 companies write about · 4 as a headwind · 0 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2018RestatedAnnual report
「There is no guarantee that the subsidy programs and other initiatives for which the Group applies will necessarily be selected.」
The company continues to disclose its policy of using public subsidies and grant programs and the possibility of not being selected. - FY2017First statedAnnual report
「There is no guarantee that the subsidy programs and other initiatives for which the Group applies will necessarily be selected.」
The company has disclosed the possibility of not being selected for public subsidies and grant programs, while stating its policy of using them to reduce the funding burden of research activities.